147 related articles for article (PubMed ID: 10082659)
1. Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis.
Okada M; Matsumori A; Ono K; Miyamoto T; Takahashi M; Sasayama S
Biochem Biophys Res Commun; 1999 Feb; 255(1):80-7. PubMed ID: 10082659
[TBL] [Abstract][Full Text] [Related]
2. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity.
Robak E; Woźniacka A; Sysa-Jedrzejowska A; Stepień H; Robak T
Eur Cytokine Netw; 2001; 12(3):445-52. PubMed ID: 11566625
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
[TBL] [Abstract][Full Text] [Related]
5. HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model.
Nakabayashi M; Morishita R; Nakagami H; Kuba K; Matsumoto K; Nakamura T; Tano Y; Kaneda Y
Diabetologia; 2003 Jan; 46(1):115-23. PubMed ID: 12637990
[TBL] [Abstract][Full Text] [Related]
6. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients.
Salgado R; Vermeulen PB; Benoy I; Weytjens R; Huget P; Van Marck E; Dirix LY
Br J Cancer; 1999 May; 80(5-6):892-7. PubMed ID: 10360671
[TBL] [Abstract][Full Text] [Related]
7. Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells.
Jiang WG; Hiscox SE; Parr C; Martin TA; Matsumoto K; Nakamura T; Mansel RE
Clin Cancer Res; 1999 Nov; 5(11):3695-703. PubMed ID: 10589789
[TBL] [Abstract][Full Text] [Related]
8. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?
Tabone MD; Landman-Parker J; Arcil B; Coudert MC; Gerota I; Benbunan M; Leverger G; Dosquet C
Clin Cancer Res; 2001 Mar; 7(3):538-43. PubMed ID: 11297245
[TBL] [Abstract][Full Text] [Related]
9. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF.
Jia H; Jezequel S; Löhr M; Shaikh S; Davis D; Soker S; Selwood D; Zachary I
Biochem Biophys Res Commun; 2001 Apr; 283(1):164-73. PubMed ID: 11322784
[TBL] [Abstract][Full Text] [Related]
10. Kringle 1-4 of hepatocyte growth factor inhibits proliferation and migration of human microvascular endothelial cells.
Kuba K; Matsumoto K; Ohnishi K; Shiratsuchi T; Tanaka M; Nakamura T
Biochem Biophys Res Commun; 2000 Dec; 279(3):846-52. PubMed ID: 11162438
[TBL] [Abstract][Full Text] [Related]
11. Heparin-binding angiogenic factors (basic fibroblast growth factor and vascular endothelial growth factor) in early neonatal life.
Malamitsi-Puchner A; Tziotis J; Protonotariou E; Xyni K; Sarandakou A; Creatsas G
Pediatr Res; 1999 Jun; 45(6):877-80. PubMed ID: 10367782
[TBL] [Abstract][Full Text] [Related]
12. Cysteine-rich and basic domain HIV-1 Tat peptides inhibit angiogenesis and induce endothelial cell apoptosis.
Jia H; Lohr M; Jezequel S; Davis D; Shaikh S; Selwood D; Zachary I
Biochem Biophys Res Commun; 2001 May; 283(2):469-79. PubMed ID: 11327725
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte growth factor stimulated angiogenesis without inflammation: differential actions between hepatocyte growth factor, vascular endothelial growth factor and basic fibroblast growth factor.
Kaga T; Kawano H; Sakaguchi M; Nakazawa T; Taniyama Y; Morishita R
Vascul Pharmacol; 2012 Aug; 57(1):3-9. PubMed ID: 22361334
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL
Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts.
Rofstad EK; Halsør EF
Cancer Res; 2000 Sep; 60(17):4932-8. PubMed ID: 10987309
[TBL] [Abstract][Full Text] [Related]
16. Human three-dimensional fibroblast cultures express angiogenic activity.
Pinney E; Liu K; Sheeman B; Mansbridge J
J Cell Physiol; 2000 Apr; 183(1):74-82. PubMed ID: 10699968
[TBL] [Abstract][Full Text] [Related]
17. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J
Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
[TBL] [Abstract][Full Text] [Related]
18. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
[TBL] [Abstract][Full Text] [Related]
19. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
Aguayo A; Kantarjian HM; Estey EH; Giles FJ; Verstovsek S; Manshouri T; Gidel C; O'Brien S; Keating MJ; Albitar M
Cancer; 2002 Nov; 95(9):1923-30. PubMed ID: 12404286
[TBL] [Abstract][Full Text] [Related]
20. Angiogenic factors: vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) are not necessarily elevated in patients with advanced renal cell carcinoma.
Edgren M; Lennernäs B; Larsson A; Kälkner KM
Anticancer Res; 2001; 21(2B):1423-9. PubMed ID: 11396226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
